Yuhan Corp and BMS will copromote Sotyktu and Zeposia
By Nho, Byung Chul | translator Kim, Jung-Ju
24.03.11 08:31:32
가나다라
0
Will copromote plaque psoriasis drug ‘Sotyktu’ and ulcerative colitis drug ‘Zeposia’ from March
The collaboration is expected to accelerate the provision of the treatments, fueled by BMS Korea’s innovative capabilities and Yuhan Corp’s sales power
▲(From the left) Hye-Young Lee, Country Manager of BMS Korea and Wook-Je Cho, CEO of Yuhan Corp
Yuhan Corp (CEO: Wook-Je Cho) announced that the company has signed a copromotion agreement with BMS Korea (Country Manager: Hye-Young Lee) for BMS’s plaque psoriasis drug ‘Sotyktu (deucravacitinib)’ and ulcerative colitis drug ‘Zeposia (ozanimod)’ on the 11th.
This strategic partnership for joint sales and marketing in Korea marks the first partnership between the two companies and will begin in March.
Sotyktu is the first TYK2 inhibitor approved by the Ministry of Food and Drug Safety for moderate-to-severe plaque psoriasis in adults. The convenient, once-daily oral treatment was approved by the MFDS in August 2023 for the treatment of moderate-to-severe plaque psoriasis i
Nho, Byung Chul(sasiman@dailypharm.com)
If you want to see the full article, please JOIN US (click)